Google Übersetzer
About
Regenxbio Inc (NASDAQ:RGNX) — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 11 2026
REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
Mar 5 2026
REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Mar 4 2026
REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Feb 25 2026
REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Feb 9 2026
REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II
Recent Videos
![REGENXBIO Inc. [RGNX] Case Explained](https://i.ytimg.com/vi/X6tZpSyJ2dc/hqdefault.jpg)
REGENXBIO Inc. [RGNX] Case Explained
Apr 13, 2026
REGENXBIO STOCK : BIG RECOVERY CANDIDATE | RGNX STOCK
Apr 12, 2026
REGENXBIO v. Sarepta — 연방순회항소법원, 유전자치료 숙주세포 특허적격성 인정
Apr 06, 2026
Shareholder Alerts for REGENXBIO Inc. (RGNX)
Mar 30, 2026
Financials
Revenue
$170.44 M
Market Cap
$440.26 M
EPS
-3.76